Cystitis and Pyelonephritis in Women
Antibiotic Selection for Cystitis and Pyelonephritis in Women
2010 Infectious Disease Society of America (IDSA) and European Society for Microbiology and Infectious Diseases (ESMID) guidelines
Target population
- Acute, uncomplicated cystitis and pyelonephritis in women
- Premenopausal, non-pregnant women without known urological abnormalities or co-morbidities (i.e. DM)
Acute uncomplicated cystitis
- Nitrofurantoin (100 mg PO BID x 5 days)
- Trimethoprim-sulfamethoxazole (1 DS tab PO BID x 3 days)
- Rising resistance rates
- Only give if local antibiogram shows <20% resistance
- Fosfomycin(3 gm PO x 1)
- Slightly less efficiacy compared to standard short-course regimens
- Pivmecillinam (400 mg PO BID x 3-7 days)
- Only available in Europe
- Fluoroquinolones (3-day course of ofloxacin, ciprofloxacin, or levofloxacin)
- Avoid if possible to minimize selection of drug-resistant organisms
Beta-lactams (3-7 day course of amoxicillin-clavulanate, cefdinir, cefaclor, cefpodoxime-proxetil)
- Avoid if possible to minimize selection of drug-resistant organisms
- Inferior efficacy compared with standard regimens
- Cephalexin less well studied
Acute Pyelonephritis
Urine analysis and urine culture should always be performed
Ciprofloxacin (500 mg po BID x 7 days) +/- ciprofloxacin 400 mg IV x 1 dose If >10% resistance to fluoroquinolones, give 1-time IV dose:
- Ceftriaxone 1 gm IV, or
- An aminoglycoside
If <10% resistance rate, alternative oral fluoroquinolone outpatient dosing options:
- Ciprofloxacin XR 1000 mg po daily x 7 days, or
- Levofloxacin 750 mg po daily x 5 days
Trimethoprim-sulfamethoxazole (1 tab DS PO BID x 14 days) 1. If resistance rate unknown, give 1-time dose of ceftriaxone 1 gm IV or aminoglycoside first
Beta-lactams (10-14 day course) 1. Because of less efficacy, give 1-time dose of ceftriaxone 1 gm IV or aminoglycoside first
References
- Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the IDSA and the ESMID. Clin Infect Dis. 2011; 52(5). [PubMed]